S

Sanofi

Global pharma company; vaccines and R&D

Field Reimbursement Manager - Allergy-ENT

Full-TimeDeadline 11/30/26
$122.3k - $176.6k
Senior
Bachelor's
Boston, MA, USA
RemoteApproximately 50% travel within the assigned geography.
Customer Experience & Support

About the job

Requirements
  • A Bachelor of Arts or Bachelor of Science degree is required.
  • At least 5 years of experience in the pharmaceutical or healthcare industry, or other relevant experience, is required.
  • Ability to travel to meetings, trainings, and programs as necessary, including additional travel within the assigned geography, is required.
  • Demonstrated success in cross-functional teamwork and working in a matrix and co-promote environment is required.
  • Interpersonal skills to manage and resolve conflict and build strong working relationships are required.
  • Ability to adapt to change and react constructively in a high-energy, fast-paced environment is required.
  • Strategic thinking, analytical, and communication skills are required.
  • Ability to achieve and maintain compliance with applicable Sanofi policies and procedures and regulatory and legal requirements, and to help monitor compliance during cross-functional team interactions, is required.
  • A valid driver's license is required.
  • Candidates must complete required fleet safety training and maintain an acceptable driving record, including a satisfactory history regarding accidents and incidents.
  • U.S.-based employees must be fully vaccinated against COVID-19 as part of their job responsibilities.
Responsibilities
  • Serve as the field subject-matter expert on patient support, access, reimbursement, prior authorization, appeals, financial assistance, and other business-related issues within the Dupixent Business Unit.
  • Work across internal stakeholders, Sales Teams, Market Access, Account Directors, Trade, Dupixent MyWay, and program vendors to deliver an exceptional customer experience.
  • Help develop and execute the national strategy by building reimbursement confidence and understanding with customers and assisting in patient pull-through efforts.
  • Serve as a subject-matter expert on Dupixent MyWay support programs, access issue resolution, financial assistance, and alternative funding options provided by the Patient Support Program.
  • Act as a point of contact for Patient Support Services (Dupixent MyWay), collaborate cross-functionally, and lead Dupixent pull-through efforts while assisting the ABM as appropriate.
  • Educate office personnel on prior authorization and appeals processes, reimbursement support through Dupixent MyWay, free drug programs, and financial assistance programs.
  • Plan and implement geographic business plans to support appropriate access to Dupixent.
  • Establish and maintain knowledge of the local and national payer landscape, including Specialty Pharmacy and Utilization Management criteria for Dupixent.
  • Establish positive and productive working relationships with key internal and external customer segments.
  • Partner with Alliance colleagues to create a culture of respect and customer focus.
  • Develop working relationships with state societies, associations, and advocacy groups as needed to support patient access and raise awareness for the Alliance, Dupixent MyWay, and Dupixent.
  • Conduct healthcare provider office visits as needed to facilitate pull-through efforts and resolve escalated issues as a HIPAA-compliant contact.
  • Work compliantly to reduce cycle time and increase conversion rates for patients prescribed Dupixent.
  • Travel approximately 50%, depending on geography, and travel to meetings, trainings, and programs when necessary.
Desired Qualifications
  • Previous experience in specialty biologics, pharmacy benefit reimbursement or access, specialty pharmacy, and/or Market Access is a plus.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...